Maraviroc Oral Solution and Venclexta Starting Pack
Determining the interaction of Maraviroc Oral Solution and Venclexta Starting Pack and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Venetoclax may increase the blood levels and effects of maraviroc. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. If possible, you should take maraviroc at least 6 hours before venetoclax to minimize the effects of the interaction. Contact your doctor if your condition changes or you experience increased side effects. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:GENERALLY AVOID: Coadministration with venetoclax may increase the plasma concentrations of drugs that are substrates of P-glycoprotein (P-gp). The proposed mechanism is decreased clearance due to inhibition of P-glycoprotein-mediated drug efflux in the intestine, liver, and/or kidney by venetoclax. Data are available for the P-gp substrate digoxin. When a single 0.5 mg dose of digoxin was coadministered with a single 100 mg dose of venetoclax, digoxin peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 35% and 9%, respectively.
MANAGEMENT: Caution is advised when venetoclax is prescribed with drugs that are P-gp substrates, particularly those with a narrow therapeutic range such as digoxin and dabigatran etexilate. Alternatives should be considered whenever possible. The manufacturer recommends that drugs sensitive to P-gp inhibition in the gastrointestinal tract be administered at least 6 hours before venetoclax. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate following the initiation or discontinuation of venetoclax.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- Cerner Multum, Inc. "Australian Product Information." O 0
- "Product Information. Venclexta (venetoclax)." AbbVie US LLC, North Chicago, IL.
Generic Name: maraviroc
Brand name: Selzentry
Synonyms: Maraviroc
Generic Name: venetoclax
Brand name: Venclexta, Venclexta Starting Pack
Synonyms: Venclexta
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Maraviroc Oral Solution-Venetoclax
- Maraviroc Oral Solution-Venipuncture CPI
- Maraviroc Oral Solution-Venipuncture PX1
- Maraviroc Oral Solution-Venlafaxine
- Maraviroc Oral Solution-Venlafaxine ER
- Maraviroc Oral Solution-Venlafaxine ER Capsules
- Venclexta Starting Pack-Maraviroc Tablets
- Venclexta Starting Pack-Marcaine
- Venclexta Starting Pack-Marcaine HCl
- Venclexta Starting Pack-Marcaine Preservative Free
- Venclexta Starting Pack-Marcaine Spinal
- Venclexta Starting Pack-Marcaine/Epinephrine